Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"JANSSEN NZ LIMITED, Consumer",Apalutamide,For the treatment of men with: metastatic hormone-sensitive prostate cancer (mHSPC) / metastatic castrate-sensitive prostate cancer (mHSPC).,Apalutamide (ERLYAND®),Options for investment,Community,Oncology Agents and Immunosuppressants
